CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Castle Creek Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Castle Creek Biosciences Inc
405 Eagleview Boulevard
Phone: (484) 713-6000p:484 713-6000 EXTON, PA  19341  United States Fax: (302) 655-5049f:302 655-5049
Business Summary
Castle Creek Biosciences, Inc. is a clinical-stage cell and gene therapy company. The Company is focused on developing and commercializing disease-modifying therapies for patients suffering from rare diseases affecting the skin and connective tissue. The Company's autologous fibroblast platform serves as the foundation for developing personalized, targeted and redosable cell-based gene therapy product candidates for both monogenic and chronic disorders. Its lead product candidate, dabocemagene autoficel (D-Fi), is in a Phase III clinical trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). D-Fi is a disease-modifying autologous cell-based gene therapy, developed to address the deficiency of functional type VII collagen protein (COL7) in patients with autosomally recessive or dominant dystrophic epidermolysis bullosa (DEB). The Company is also developing a second product candidate, FCX-013, for the treatment of moderate to severe localized scleroderma.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-YesYesYes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202112/31/2020YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Founder Jeffrey S.Aronin 55
President, Chief Executive Officer, Director MatthewGantz
Executive Vice President - Research and Development Timothy M.Cunniff
Senior Vice President - Regulatory and Quality Affairs JeffHesselberg 1/1/2022
Chief Technology Officer ChristopherBallas

Business Names
Business Name
Castle Creek Biosciences, LLC
Isolagen International, S.A.
Novavita Thera, Inc.

General Information
Number of Employees: 53 (As of 6/30/2021)
Outstanding Shares: 8,500 (As of 3/31/2021)
Federal Tax Id: 831984773
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 9, 2024